5.84
+0.04(+0.69%)
Currency In USD
| Previous Close | 5.8 |
| Open | 5.89 |
| Day High | 6.08 |
| Day Low | 5.57 |
| 52-Week High | 46.8 |
| 52-Week Low | 3.76 |
| Volume | 155,913 |
| Average Volume | 177,235 |
| Market Cap | 35.71M |
| PE | -0.33 |
| EPS | -17.47 |
| Moving Average 50 Days | 7.29 |
| Moving Average 200 Days | 16.35 |
| Change | 0.04 |
If you invested $1000 in Aligos Therapeutics, Inc. (ALGS) since IPO date, it would be worth $15.73 as of May 18, 2025 at a share price of $5.84. Whereas If you bought $1000 worth of Aligos Therapeutics, Inc. (ALGS) shares 3 years ago, it would be worth $206.73 as of May 18, 2025 at a share price of $5.84.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Aligos Therapeutics Presents Positive Data at the EASL Congress 2025
GlobeNewswire Inc.
May 08, 2025 12:00 PM GMT
SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, t
Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025
GlobeNewswire Inc.
Apr 29, 2025 12:30 PM GMT
SOUTH SAN FRANCISCO, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, tod
Aligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025
GlobeNewswire Inc.
Apr 23, 2025 8:05 PM GMT
SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases,